Milea Timbergen

323 38 . Crago AM, Denton B, Salas S, Dufresne A, Mezhir JJ, Hameed M, et al. A prognostic nomogram for prediction of recurrence in desmoid fibromatosis. Ann Surg. 2013;258(2):347-353. 39 . Colombo C, Urbini M, Astolfi A, Collini P, Indio V, Belfiore A, et al. Novel intra-genic large deletions of CTNNB1 gene identified in WT desmoid-type fibromatosis. Genes Chromosomes Cancer. 2018;57(10):495-503. 40 . Crago AM, Chmielecki J, Rosenberg M, O’Connor R, Byrne C, Wilder FG, et al. Near universal detection of alterations in CTNNB1 and Wnt pathway regulators in desmoid-type fibromatosis by whole-exome sequencing and genomic analysis. Genes Chromosomes Cancer. 2015;54(10):606-615. 41 . Penel N, Coindre JM, Bonvalot S, Italiano A, Neuville A, Le Cesne A, et al. Management of desmoid tumours: A nationwide survey of labelled reference centre networks in France. Eur J Cancer. 2016;58:90-96. 42 . Lee JC, Thomas JM, Phillips S, Fisher C, Moskovic E. Aggressive fibromatosis: MRI features with pathologic correlation. American Journal of Roentgenology. 2006;186(1):247-254. 43 . Rutman AM, Kuo MD. Radiogenomics: creating a link between molecular diagnostics and diagnostic imaging. Eur J Radiol. 2009;70(2):232-241. 44 . Mazurowski MA. Radiogenomics: what it is and why it is important. J AmColl Radiol. 2015;12(8):862-866. 45 . Gevaert O, Echegaray S, Khuong A, Hoang CD, Shrager JB, Jensen KC, et al. Predictive radiogenomics modeling of EGFR mutation status in lung cancer. Sci Rep. 2017;7:41674. 46 . Karlo CA, Di Paolo PL, Chaim J, Hakimi AA, Ostrovnaya I, Russo P, et al. Radiogenomics of clear cell renal cell carcinoma: associations between CT imaging features and mutations. Radiology. 2014;270(2):464-471. 47 . Grimm LJ. Breast MRI radiogenomics: Current status and research implications. J Magn Reson Imaging. 2016;43(6):1269-1278. 48 . Briand S, Barbier O, Biau D, Bertrand-Vasseur A, Larousserie F, Anract P, et al. Wait-and-see policy as a first-line management for extra-abdominal desmoid tumors. Journal of Bone and Joint Surgery - American Volume. 2014;96(8):631-638. 49 . Penel N, Le Cesne A, Bonvalot S, Giraud A, Bompas E, Rios M, et al. Surgical versus non-surgical approach in primary desmoid-type fibromatosis patients: A nationwide prospective cohort from the French Sarcoma Group. Eur J Cancer. 2017;83:125-131. 50 . Bonvalot S, Eldweny H, Haddad V, Rimareix F, Missenard G, Oberlin O, et al. Extra-abdominal primary fibromatosis: Aggressive management could be avoided in a subgroup of patients. Eur J Surg Oncol. 2008;34(4):462-468. 51 . Bonvalot S, Ternes N, Fiore M, Bitsakou G, Colombo C, Honore C, et al. Spontaneous regression of primary abdominal wall desmoid tumors: more common than previously thought. Ann Surg Oncol. 2013;20(13):4096-4102. 52 . Colombo C, Miceli R, Le Pechoux C, Palassini E, Honore C, Stacchiotti S, et al. Sporadic extra abdominal wall desmoid-type fibromatosis: surgical resection can be safely limited to a minority of patients. European Journal of Cancer. 2015:186-192. 53 . Mullen JT, DeLaney TF, Rosenberg AE, Le L, Iafrate AJ, Kobayashi W, et al. β-catenin mutation status and outcomes in sporadic desmoid tumors. Oncologist. 2013;18(9):1043-1049. 54 . Domont J, Benard J, Lacroix L, Salas S, Dufresne A, Terrier P, et al. Detection of beta-catenin mutations in primary extra-abdominal fibromatosis (EAF): An ancillary diagnostic tool. Journal of Clinical Oncology. 2008;26:10518-10518. 55 . Rigaux P, Lefebvre-Kuntz D, Penel N, Desmoide SOS. Pain burden in desmoid tumor patients: a survey of the French Advocacy Group SOS Desmoid. Bull Cancer. 2015;102(3):213-216. 56 . Johnson C, Aaronson N, Blazeby JM, Bottomley A, Fayers P, Koller M, et al. Guidelines for Developing questionnaire Modules, fourth edition: EORTC Quality of Life Group; 2011 [updated April 2011. Available from: http://www.eortc.org/app/uploads/sites/2/2018/02/guidelines_for_developing_questionnaire-_final.pdf. 11